Leveraging Blood Components for 3D Printing Applications Through Programmable Ink Engineering Approaches.
Sobreiro-Almeida R., Santos SC., Decarli MC., Costa M., Correia TR., Babilotte J.
Laboratory Study, published in Adv Sci (Weinh) (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Adv Sci (Weinh) (2024)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39450696
- PMCID
- PMC11653660
- DOI
- 10.1002/advs.202406569
- Citations
- 5
Abstract (original English)
This study proposes a tunable ink engineering methodology to allow 3D printing processability of highly bioactive but otherwise low-viscous and unprintable blood-derived materials. The hypothesis relies on improving the viscoelasticity and shear thinning behavior of platelet lysates (PL) and albumins (BSA) solutions by covalent coupling, enabling simultaneous extrusion and photocrosslinking upon filament deposition. The available amine groups on proteins (PL and BSA) are exploited for coupling with carboxyl groups present in methacrylated proteins (hPLMA and BSAMA), by leveraging carbodiimide chemistry. This reaction enabled the creation of a pre-gel from these extremely low-viscous materials (≈ 1 Pa), with precise tuning of the reaction, resulting in inks with a range of controlled viscosities and elasticities. Shape-fidelity analysis is performed on 3D-printed multilayered constructs, demonstrating the ability to reach clinically relevant sizes (>2 cm in size). After photocrosslinking, the scaffolds showcased a mechanically robust structure with sustained protein release over time. Bioactivity is evaluated using human adipose-derived stem cells, resulting in increased viability and metabolic activity over time. The herein described research methodology widens the possibilities for the use of low-viscosity materials in 3D printing but also enables the direct application of pat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.